{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:40:40Z","timestamp":1790667640519,"version":"4.1.0"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK114015"],"award-info":[{"award-number":["DK114015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jconrel.2020.07.034","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T15:32:03Z","timestamp":1595431923000},"page":"100-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"special_numbering":"C","title":["Bile acid transporter-mediated oral drug delivery"],"prefix":"10.1016","volume":"327","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-4259","authenticated-orcid":false,"given":"Feiyang","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-1924","authenticated-orcid":false,"given":"You Han","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.07.034_bb0005","first-page":"8525679","article-title":"Nanotechnology based approaches for enhancing Oral bioavailability of poorly water soluble antihypertensive drugs","volume":"2016","author":"Sharma","year":"2016","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/09687688.2010.497971","article-title":"A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers","volume":"27","author":"Ganta","year":"2010","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1461-5347(00)00247-9","article-title":"Recent technological advances in oral drug delivery - a review","volume":"3","author":"Sastry","year":"2000","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent progress in oral drug delivery systems for biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpb.2012.07.014","article-title":"pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide\/protein drugs and poorly water-soluble drugs","volume":"82","author":"Wang","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0030","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bbapap.2012.10.003","article-title":"Accessing the reproducibility and specificity of pepsin and other aspartic proteases","volume":"1834","author":"Ahn","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12342","article-title":"Mucus as a barrier to drug delivery - understanding and mimicking the barrier properties","volume":"116","author":"Boegh","year":"2015","journal-title":"Basic Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0040","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/acsnano.5b00028","article-title":"Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin","volume":"9","author":"Shan","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0045","doi-asserted-by":"crossref","first-page":"84164","DOI":"10.1039\/C6RA18724B","article-title":"Effects of surface hydrophilic properties of PEG-based mucus-penetrating nanostructured lipid carriers on oral drug delivery","volume":"6","author":"Li","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41578-019-0156-6","article-title":"Materials for oral delivery of proteins and peptides","volume":"5","author":"Brown","year":"2020","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2019.04.032","article-title":"Mucin binding to therapeutic molecules: the case of antimicrobial agents used in cystic fibrosis","volume":"564","author":"Butnarasu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/biomimetics4020032","article-title":"Interaction between Chitosan and Mucin: fundamentals and applications","volume":"4","author":"Collado-Gonzalez","year":"2019","journal-title":"Biomimetics"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0065","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1080\/10717544.2018.1501119","article-title":"The challenges of oral drug delivery via nanocarriers","volume":"25","author":"Reinholz","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0070","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/jps.21961","article-title":"Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models","volume":"99","author":"Linnankoski","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/mi.2010.5","article-title":"Multiple facets of intestinal permeability and epithelial handling of dietary antigens","volume":"3","author":"Menard","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajps.2014.09.004","article-title":"A review on phospholipids and their main applications in drug delivery systems","volume":"10","author":"Li","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jps.20792","article-title":"Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications","volume":"96","author":"Kaufmann","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/DTI.S12519","article-title":"P-glycoprotein inhibition for optimal drug delivery","volume":"7","author":"Amin","year":"2013","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0100","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","article-title":"Improving drug solubility for oral delivery using solid dispersions","volume":"50","author":"Leuner","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/2231-4040.82950","article-title":"Nanosuspension: an approach to enhance solubility of drugs","volume":"2","author":"Patel","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0115","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.2147\/IJN.S141504","article-title":"A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies","volume":"12","author":"Narayan","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0120","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s11095-010-0323-3","article-title":"Bottom-up preparation techniques for nanocrystals of lipophilic drugs","volume":"28","author":"de Waard","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/10837450.2017.1287729","article-title":"Design of microemulsion system suitable for the oral delivery of poorly aqueous soluble beta-carotene","volume":"23","author":"Peng","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11120629","article-title":"Using supercritical fluid technology as a green alternative during the preparation of drug delivery systems","volume":"11","author":"Chakravarty","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11095-012-0889-z","article-title":"Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs","volume":"30","author":"Gao","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/03639045.2016.1269122","article-title":"Current and evolving approaches for improving the oral permeability of BCS class III or analogous molecules","volume":"43","author":"Dave","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0145","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","article-title":"Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges","volume":"17","author":"Wen","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/0250-474X.42967","article-title":"Protein and peptide drug delivery: oral approaches","volume":"70","author":"Shaji","year":"2008","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14712598.1.2.159","article-title":"Prodrug based optimal drug delivery via membrane transporter\/receptor","volume":"1","author":"Yang","year":"2001","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","article-title":"A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives","volume":"24","author":"Muheem","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fnut.2019.00093","article-title":"Vitamin B12 intake from animal foods, biomarkers, and health aspects","volume":"6","author":"Obeid","year":"2019","journal-title":"Front. Nutr."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/17425247.2011.539200","article-title":"Vitamin B12 in drug delivery: breaking through the barriers to a B12 bioconjugate pharmaceutical","volume":"8","author":"Clardy","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0175","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.2147\/IJN.S218944","article-title":"Investigation of vitamin B12-modified amphiphilic sodium alginate derivatives for enhancing the oral delivery efficacy of peptide drugs","volume":"14","author":"Long","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0180","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/anie.200800865","article-title":"Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs","volume":"48","author":"Petrus","year":"2009","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0185","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4161\/mabs.26507","article-title":"NFkappaB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn","volume":"5","author":"Cervenak","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0190","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s11095-013-1212-3","article-title":"Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis","volume":"31","author":"Hornby","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007049","article-title":"Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery","volume":"5","author":"Pridgen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0205","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1016\/j.vaccine.2014.07.036","article-title":"Development of serum antibodies during early infancy in rhesus macaques: implications for humoral immune responses to vaccination at birth","volume":"32","author":"Shen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0210","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12972","article-title":"Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns","volume":"80","author":"Lozano","year":"2018","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0215","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0220","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0225","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/mp2005388","article-title":"Folic acid functionalized nanoparticles for enhanced oral drug delivery","volume":"9","author":"Roger","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0230","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.biomaterials.2012.10.003","article-title":"Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery","volume":"34","author":"Du","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0235","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3109\/10717544.2015.1058433","article-title":"A novel ligand conjugated nanoparticles for oral insulin delivery","volume":"23","author":"Liu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-5793(96)00778-8","article-title":"Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of beta-lactam antibiotics","volume":"392","author":"Sai","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0245","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0250","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1211\/jpp.57.9.0013","article-title":"Role of monocarboxylic acid transporters in the cellular uptake of NSAIDs","volume":"57","author":"Choi","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/bdd.479","article-title":"Intestinal absorption characteristics of ketoprofen in rats","volume":"27","author":"Choi","year":"2006","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0260","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2174\/156800805774912953","article-title":"Amino acid transporter ATB0,+ as a delivery system for drugs and prodrugs","volume":"5","author":"Ganapathy","year":"2005","journal-title":"Curr. Drug Targets Immune Endocr. Metabol. Disord."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0265","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/0006-2952(92)90649-4","article-title":"Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs","volume":"43","author":"Mizuma","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0270","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/17425247.2012.697055","article-title":"Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach","volume":"9","author":"Dahan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0275","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.biocel.2013.04.012","article-title":"Transport and biological activities of bile acids","volume":"45","author":"Zwicker","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0280","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1021\/acs.jproteome.5b00676","article-title":"Distinct plasma bile acid profiles of biliary atresia and neonatal hepatitis syndrome","volume":"14","author":"Zhou","year":"2015","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0285","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0290","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile acid metabolism in liver pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0295","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3748\/wjg.15.804","article-title":"Bile acids: chemistry, physiology, and pathophysiology","volume":"15","author":"Monte","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0300","series-title":"StatPearls","article-title":"Physiology, bile acids","author":"Chen","year":"2020"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1021\/js950326j","article-title":"Aggregation behavior of bile salts in aqueous solution","volume":"85","author":"Coello","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0310","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/eci.12161","article-title":"New insights into the molecular mechanism of intestinal fatty acid absorption","volume":"43","author":"Wang","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0315","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Comp. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0320","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s11095-007-9289-1","article-title":"Bile acid transporters: structure, function, regulation and pathophysiological implications","volume":"24","author":"Alrefai","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0325","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1631\/jzus.B1900158","article-title":"Bile-ology: from bench to bedside","volume":"20","author":"Jin","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0330","doi-asserted-by":"crossref","first-page":"G801","DOI":"10.1152\/ajpgi.1995.269.6.G801","article-title":"Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile","volume":"269","author":"Meier","year":"1995","journal-title":"Am. J. Physiol. Gastr. Liver"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-642-14541-4_5","article-title":"The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation","author":"Stieger","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0340","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.physiol.64.082201.100300","article-title":"Bile salt transporters","volume":"64","author":"Meier","year":"2002","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0345","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0350","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1194\/jlr.M700417-JLR200","article-title":"Liver receptor homolog 1 transcriptionally regulates human bile salt export pump expression","volume":"49","author":"Song","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0355","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/00498250802040584","article-title":"Bile acid transporters in health and disease","volume":"38","author":"Kosters","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0360","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1389200216666151103115454","article-title":"Bile acids in physiology, pathology and pharmacology","volume":"17","author":"Marin","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0365","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1021\/mp500193g","article-title":"Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components","volume":"11","author":"Birru","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0370","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000084","article-title":"Intestinal lipid absorption and lipoprotein formation","volume":"25","author":"Hussain","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0375","first-page":"E1183","article-title":"Intestinal lipid absorption","volume":"296","author":"Iqbal","year":"2009","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0380","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41575-019-0250-7","article-title":"Regulation of intestinal lipid metabolism: current concepts and relevance to disease","volume":"17","author":"Ko","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0385","first-page":"G715","article-title":"Formation and transport of chylomicrons by enterocytes to the lymphatics","volume":"250","author":"Tso","year":"1986","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0390","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.addr.2011.05.019","article-title":"Intestinal lymphatic transport for drug delivery","volume":"63","author":"Yanez","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0395","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000626","article-title":"Intestinal lymphatic vessels and their role in chylomicron absorption and lipid homeostasis","volume":"30","author":"Hokkanen","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0400","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1111\/j.1749-6632.2010.05716.x","article-title":"Mechanisms of chylomicron uptake into lacteals","volume":"1207","author":"Dixon","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0405","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17425247.2018.1503249","article-title":"Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs","volume":"15","author":"Managuli","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0410","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: lipid-based nanoformulations","volume":"8","author":"Ali Khan","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0415","doi-asserted-by":"crossref","first-page":"254s","DOI":"10.18433\/jpps30217","article-title":"Lymphatic drug absorption via the enterocytes: pharmacokinetic simulation, modeling, and considerations for optimal drug development","volume":"21","author":"Brocks","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0420","first-page":"247","article-title":"Recent advances in lymphatic targeted drug delivery system for tumor metastasis","volume":"11","author":"Zhang","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0425","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0074-7696(08)61346-7","article-title":"M cells in Peyer\u2019s patches of the intestine","volume":"167","author":"Gebert","year":"1996","journal-title":"Int. Rev. Cytol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0430","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3748\/wjg.v13.i10.1477","article-title":"Intestinal M cells: the fallible sentinels?","volume":"13","author":"Miller","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0435","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-2275(20)43096-2","article-title":"Mechanisms for the intestinal absorption of bile acids","volume":"9","author":"Dietschy","year":"1968","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0440","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/mp060022d","article-title":"Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target","volume":"3","author":"Balakrishnan","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0445","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nature10450","article-title":"Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT","volume":"478","author":"Hu","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0450","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nature12811","article-title":"Structural basis of the alternating-access mechanism in a bile acid transporter","volume":"505","author":"Zhou","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0455","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/prot.24796","article-title":"Mechanistic studies of the apical sodium-dependent bile acid transporter","volume":"83","author":"Alhadeff","year":"2015","journal-title":"Proteins"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0460","article-title":"Functional transformations of bile acid transporters induced by high-affinity macromolecules","volume":"4","author":"Al-Hilal","year":"2014","journal-title":"Sci. Rep. U.K."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0465","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1021\/acsnano.8b04315","article-title":"Oral nanoparticles exhibit specific high-efficiency intestinal uptake and lymphatic transport","volume":"12","author":"Kim","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0470","doi-asserted-by":"crossref","first-page":"42283","DOI":"10.1074\/jbc.M507454200","article-title":"Ileal bile acid-binding protein, functionally associated with the farnesoid X receptor or the ileal bile acid transporter, regulates bile acid activity in the small intestine","volume":"280","author":"Nakahara","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0475","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.bbagen.2017.07.004","article-title":"The long variant of human ileal bile acid-binding protein associated with colorectal cancer exhibits sub-cellular localization and lipid binding behaviour distinct from those of the common isoform","volume":"1861","author":"D\u2019Onofrio","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0480","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1194\/jlr.M021733","article-title":"Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXR alpha","volume":"53","author":"Fang","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0485","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1074\/jbc.M412752200","article-title":"The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter","volume":"280","author":"Dawson","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0490","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jcmgh.2018.01.015","article-title":"OSTalpha-OSTbeta guards the Ileal enterocyte from the accumulation of toxic levels of bile acids","volume":"5","author":"Boyer","year":"2018","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0495","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.mam.2012.11.005","article-title":"The heteromeric organic solute transporter, OSTalpha-OSTbeta\/SLC51: a transporter for steroid-derived molecules","volume":"34","author":"Ballatori","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0500","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-0030-1253226","article-title":"Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis","volume":"30","author":"Soroka","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0505","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-1007225","article-title":"Hepatocellular sinusoidal membrane organic anion transport and transporters","volume":"16","author":"Wolkoff","year":"1996","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0510","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.29251","article-title":"Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice","volume":"66","author":"Slijepcevic","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0515","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1016\/j.febslet.2006.07.082","article-title":"Nuclear bile acid receptor FXR as pharmacological target: are we there yet?","volume":"580","author":"Modica","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2012.05.004","article-title":"FXR signaling in the enterohepatic system","volume":"368","author":"Matsubara","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0525","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.bcp.2005.03.019","article-title":"Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor","volume":"69","author":"Campana","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0530","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2362.1996.tb02383.x","article-title":"Bile acid transport systems as pharmaceutical targets","volume":"26","author":"Kramer","year":"1996","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0535","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1152\/ajplegacy.1970.219.2.487","article-title":"Ileal bile salt transport - in-vivo studies of effect of substrate ionization on activity","volume":"219","author":"Lack","year":"1970","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0540","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1289\/ehp.793379","article-title":"Properties and biological significance of the Ileal bile-salt transport-system","volume":"33","author":"Lack","year":"1979","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0545","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1152\/ajplegacy.1966.210.5.1142","article-title":"Intestinal bile salt transport - structure-activity relationships and other properties","volume":"210","author":"Lack","year":"1966","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0550","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1172\/JCI117722","article-title":"Cloning and molecular characterization of the ontogeny of a rat Ileal sodium-dependent bile-acid transporter","volume":"95","author":"Shneider","year":"1995","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0555","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/12081859","article-title":"Exploitation of bile acid transport systems in prodrug design","volume":"12","author":"Sievanen","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0560","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0022-2275(20)38284-5","article-title":"3-Diazirine-derivatives of bile-salts for Photoaffinity-labeling","volume":"30","author":"Kramer","year":"1989","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0565","doi-asserted-by":"crossref","first-page":"10621","DOI":"10.1016\/S0021-9258(17)34105-4","article-title":"Intestinal-absorption of peptides by coupling to bile-acids","volume":"269","author":"Kramer","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0570","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/mp034010t","article-title":"Increased acyclovir oral bioavailability via a bile acid conjugate","volume":"1","author":"Tolle-Sander","year":"2004","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0575","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bmcl.2004.10.027","article-title":"Synthesis and biological evaluation of novel steroidal pyrazoles as substrates for bile acid transporters","volume":"15","author":"Bhat","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0580","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1021\/bc100273w","article-title":"Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid","volume":"21","author":"Zheng","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0585","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jps.22332","article-title":"Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT)","volume":"100","author":"Rais","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0590","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s11095-006-0219-4","article-title":"Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation","volume":"23","author":"Balakrishnan","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0595","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1023\/A:1012044526054","article-title":"Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity","volume":"14","author":"Kagedahl","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0600","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijpharm.2016.06.139","article-title":"Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption","volume":"511","author":"Zhang","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0605","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.biotechadv.2016.11.002","article-title":"3D tumor spheroids: an overview on the tools and techniques used for their analysis","volume":"34","author":"Costa","year":"2016","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01283","article-title":"Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles","volume":"9","author":"Pavlovic","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0615","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1021\/mp400179v","article-title":"Ion pairing with bile salts modulates intestinal permeability and contributes to food-drug interaction of BCS class III compound trospium chloride","volume":"10","author":"Heinen","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0620","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.50.5.1869-1871.2006","article-title":"Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats","volume":"50","author":"Lee","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0625","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jconrel.2007.07.013","article-title":"Liphophilic complexation of heparin based on bile acid for oral delivery","volume":"123","author":"Lee","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0630","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.xphs.2017.12.012","article-title":"Bile acid as an effective absorption enhancer for oral delivery of epidermal growth factor receptor-targeted hybrid peptide","volume":"107","author":"Gaowa","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0635","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1016\/j.biomaterials.2014.04.050","article-title":"Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid","volume":"35","author":"Alam","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0640","doi-asserted-by":"crossref","first-page":"73986","DOI":"10.1039\/C6RA10978K","article-title":"Design and strategies for bile acid mediated therapy and imaging","volume":"6","author":"Nurunnabi","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23102615","article-title":"Amide bond activation of biological molecules","volume":"23","author":"Mahesh","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0650","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4314\/tjpr.v13i11.4","article-title":"Enhancing effect of bile salts on gastrointestinal absorption of insulin","volume":"13","author":"Jalali","year":"2014","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0655","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0928-0987(99)00093-7","article-title":"Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine","volume":"10","author":"Michael","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0660","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/mf.2008.30.2.1159652","article-title":"Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics","volume":"30","author":"Al-Salami","year":"2008","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0665","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","volume":"12","author":"Din","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0670","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jconrel.2016.06.016","article-title":"Nanoparticles for oral delivery: Design, evaluation and state-of-the-art","volume":"240","author":"Date","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0675","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.apsb.2018.06.005","article-title":"Adapting liposomes for oral drug delivery","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0680","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4155\/tde.15.69","article-title":"Oral delivery of liposomes","volume":"6","author":"Wu","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0685","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2014.00138","article-title":"Orally administered liposomal formulations for colon targeted drug delivery","volume":"5","author":"Hua","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0690","first-page":"289","article-title":"Potential of liposomes for enhancement of oral drug absorption","volume":"14","author":"Daeihamed","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0695","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/02652049509051125","article-title":"Polymer-coated liposomes: improved liposome stability and release of cytosine arabinoside (Ara-C)","volume":"12","author":"Sehgal","year":"1995","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0700","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0168-3659(91)90140-9","article-title":"Polymer-coated liposomes - stability and release of Asa from carboxymethyl chitin-coated liposomes","volume":"17","author":"Dong","year":"1991","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0705","first-page":"3679","article-title":"Functional coating of liposomes using a folate-polymer conjugate to target folate receptors","volume":"7","author":"Watanabe","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0710","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.xphs.2019.01.027","article-title":"A delivery system for oral administration of proteins\/peptides through bile acid transport channels","volume":"108","author":"Wu","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0715","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2018.12.028","article-title":"Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model","volume":"294","author":"Suzuki","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0720","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/S0264-410X(00)00537-5","article-title":"Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)","volume":"19","author":"Conacher","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0725","article-title":"Bilosome: a bile salt based novel carrier system gaining interest in pharmaceutical research","volume":"7","author":"Rajput","year":"2017","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0730","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.vaccine.2003.11.067","article-title":"Optimisation of a lipid based oral delivery system containing A\/panama influenza haemagglutinin","volume":"22","author":"Mann","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0735","doi-asserted-by":"crossref","first-page":"58","DOI":"10.18433\/J3K01M","article-title":"Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)","volume":"11","author":"Shukla","year":"2008","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0740","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1476-5381.2011.01452.x","article-title":"Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes","volume":"164","author":"Shukla","year":"2011","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0745","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2009.04.022","article-title":"Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt","volume":"376","author":"Chen","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0750","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.2147\/IJN.S82558","article-title":"Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine","volume":"10","author":"Elnaggar","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0755","doi-asserted-by":"crossref","first-page":"119120","DOI":"10.1016\/j.ijpharm.2020.119120","article-title":"Bile acid transporter mediated STC\/Soluplus self-assembled hybrid nanoparticles for enhancing the oral drug bioavailability","volume":"579","author":"Zhang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0760","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2013.04.024","article-title":"Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy","volume":"170","author":"Khatun","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0765","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.carbpol.2012.07.016","article-title":"Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles","volume":"90","author":"Khatun","year":"2012","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0770","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2217\/nnm.15.36","article-title":"Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles","volume":"10","author":"Chaturvedi","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0775","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s11095-016-1954-9","article-title":"A mixed micelle formulation for Oral delivery of vitamin K","volume":"33","author":"Sun","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0780","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/aps.2010.55","article-title":"Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate\/phospholipid-mixed micelles","volume":"31","author":"Yu","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0785","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/bc100594v","article-title":"Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery","volume":"22","author":"Kim","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0790","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.biomaterials.2007.10.026","article-title":"The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles","volume":"29","author":"Samstein","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0795","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/mp900163d","article-title":"Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter","volume":"6","author":"Zheng","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0800","doi-asserted-by":"crossref","first-page":"32394","DOI":"10.1074\/jbc.M113.518555","article-title":"Transmembrane domain II of the human bile acid transporter SLC10A2 coordinates sodium translocation","volume":"288","author":"Sabit","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0805","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nature10450","article-title":"Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT","volume":"478","author":"Hu","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0810","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biomaterials.2017.09.022","article-title":"Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex","volume":"147","author":"Park","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0815","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1515\/bc.2011.017","article-title":"Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery","volume":"392","author":"Kramer","year":"2011","journal-title":"Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0820","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jps.23413","article-title":"Enhanced oral absorption of ibandronate via complex formation with bile acid derivative","volume":"102","author":"Park","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0825","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2005.05.016","article-title":"Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts","volume":"106","author":"Song","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0830","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1021\/acsami.6b15151","article-title":"Transmembrane pathways and mechanisms of rod-like paclitaxel nanocrystals through MDCK polarized monolayer","volume":"9","author":"Deng","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0835","article-title":"Routes and mechanisms of extracellular vesicle uptake","volume":"3","author":"Mulcahy","year":"2014","journal-title":"J. Extracell. Ves."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0840","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1083\/jcb.201608071","article-title":"Regulation of clathrin-mediated endocytosis by hierarchical allosteric activation of AP2","volume":"216","author":"Kadlecova","year":"2017","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0845","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrm2447","article-title":"Shaping cups into phagosomes and macropinosomes","volume":"9","author":"Swanson","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0850","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ajps.2018.06.004","article-title":"Small GTPases: structure, biological function and its interaction with nanoparticles","volume":"14","author":"Song","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0855","doi-asserted-by":"crossref","first-page":"G489","DOI":"10.1152\/ajpgi.00237.2007","article-title":"Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts","volume":"294","author":"Annaba","year":"2008","journal-title":"Am. J. Physiol. Gastr. Liver"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0860","doi-asserted-by":"crossref","first-page":"28110","DOI":"10.1039\/C5RA28018D","article-title":"Enhanced hepatic-targeted delivery via oral administration using nanoliposomes functionalized with a novel DSPE-PEG-cholic acid conjugate","volume":"6","author":"Li","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0865","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1021\/acs.molpharmaceut.7b00662","article-title":"N-deoxycholic acid-N,O-hydroxyethyl chitosan with a sulfhydryl modification to enhance the oral absorptive efficiency of paclitaxel","volume":"14","author":"Yu","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0870","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.2147\/IJN.S209722","article-title":"Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative","volume":"14","author":"Pangeni","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0875","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2017.10.022","article-title":"Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery","volume":"151","author":"Fan","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0880","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1039\/C7NR06063G","article-title":"The combination of endolysosomal escape and basolateral stimulation to overcome the difficulties of \"easy uptake hard transcytosis\" of ligand-modified nanoparticles in oral drug delivery","volume":"10","author":"Cui","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0885","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-015-0041-1","article-title":"The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration","volume":"4","author":"Hu","year":"2015","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0895","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2015.08.086","article-title":"Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability","volume":"495","author":"He","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0890","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrm3588","article-title":"Organization of the ER-Golgi interface for membrane traffic control","volume":"14","author":"Brandizzi","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0900","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.tcb.2014.04.007","article-title":"Secretory cargo sorting at the trans-Golgi network","volume":"24","author":"Kienzle","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0905","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1172\/JCI108465","article-title":"The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell","volume":"58","author":"Westergaard","year":"1976","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0910","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2013.05.021","article-title":"Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats","volume":"452","author":"Zhang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0915","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1039\/C9NR03025E","article-title":"Biological fate of ingested lipid-based nanoparticles: current understanding and future directions","volume":"11","author":"Wang","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0920","first-page":"320","article-title":"Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel","volume":"71","author":"Zhang","year":"2016","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0925","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1021\/acs.molpharmaceut.8b00708","article-title":"Immense insulin intestinal uptake and lymphatic transport using bile acid conjugated partially uncapped liposome","volume":"15","author":"Kim","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0930","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2019.08.027","article-title":"Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle","volume":"311-312","author":"Kim","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0935","first-page":"4797","article-title":"Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge","volume":"10","author":"Arzani","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0940","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/2230-973X.160844","article-title":"Mesoporous silica nanoparticles in target drug delivery system: a review","volume":"5","author":"Bharti","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0945","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1002\/anie.200604488","article-title":"Mesoporous materials for drug delivery","volume":"46","author":"Vallet-Regi","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0950","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp200287c","article-title":"Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs","volume":"9","author":"Zhang","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0955","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/adhm.201200176","article-title":"Folic acid-modified mesoporous silica nanoparticles for cellular and nuclear targeted drug delivery","volume":"2","author":"Porta","year":"2013","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0960","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/DDDT.S122984","article-title":"Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting","volume":"11","author":"Choi","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0965","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2020.04.008","article-title":"A multiaspect study on transcytosis mechanism of sorafenib nanogranules engineered by high -gravity antisolvent precipitation","volume":"323","author":"Yin","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.07.034_bb0970","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2020.07.034_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11010041","article-title":"Application of permeation enhancers in oral delivery of macromolecules: an update","volume":"11","author":"Maher","year":"2019","journal-title":"Pharmaceutics"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920304181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920304181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:09:14Z","timestamp":1718420954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920304181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":195,"alternative-id":["S0168365920304181"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.034","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acid transporter-mediated oral drug delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}